Biotech

acquisition merger arrows
Biotech

AbbVie ends development of IL-1 asset in ulcerative colitis

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis after a phase 2 study revealed insufficient efficacy results.
Gabrielle Masson Jul 31, 2025 12:32pm
Stop sign

Nuvectis axes ovarian cancer program after seeing phase 1b data

Jul 31, 2025 9:15am
Rethinking Clinical Trial Data in the Era of Decentralization

Rethinking Clinical Trial Data in the Era of Decentralization

Jul 28, 2025 8:00am
workers

Fierce Biotech Layoff Tracker 2025: Moderna, Merck & more

Jul 31, 2025 8:45am
Carl Sailer on AI market trends and strategic planning in biotech

Carl Sailer on AI, market trends, and strategic planning in biotech

Oct 28, 2024 8:00pm
Winding 3D road with dollar bills

Frazier Life Sciences raises $1.3B for early-stage biotech fund

Jul 31, 2025 7:54am